• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Med Chem . Development of chalcone-like derivatives and their biological and mechanistic investigations as novel influenza nuclear export inh

tetano

Editor, Senior Moderator
Eur J Med Chem


. 2023 Sep 29:261:115845.
doi: 10.1016/j.ejmech.2023.115845. Online ahead of print. Development of chalcone-like derivatives and their biological and mechanistic investigations as novel influenza nuclear export inhibitors

Chuanfeng Liu[SUP] 1 [/SUP], Ying Zhang[SUP] 2 [/SUP], Ping Li[SUP] 3 [/SUP], Huinan Jia[SUP] 2 [/SUP], Han Ju[SUP] 2 [/SUP], Jiwei Zhang[SUP] 2 [/SUP], Edeildo Ferreira da Silva-Júnior[SUP] 4 [/SUP], Sunanda Samanta[SUP] 5 [/SUP], Parimal Kar[SUP] 6 [/SUP], Bing Huang[SUP] 7 [/SUP], Xinyong Liu[SUP] 8 [/SUP], Peng Zhan[SUP] 9 [/SUP]



Affiliations
Abstract

Concerning the emergence of resistance to current anti-influenza drugs, our previous phenotypic-based screening study identified the compound A9 as a promising lead compound. This chalcone analog, containing a 2,6-dimethoxyphenyl moiety, exhibited significant inhibitory activity against oseltamivir-resistant strains (H1N1 pdm09), with an EC[SUB]50[/SUB] value of 1.34 μM. However, it also displayed notable cytotoxicity, with a CC[SUB]50[/SUB] value of 41.46 μM. Therefore, compound A9 was selected as a prototype structure for further structural optimization in this study. Initially, it was confirmed that the substituting the α,β-unsaturated ketone with pent-1,4-diene-3-one as a linker group significantly reduced the cytotoxicity of the final compounds. Subsequently, the penta-1,4-dien-3-one group was utilized as a privileged fragment for further structural optimization. Following two subsequent rounds of optimizations, we identified compound IIB-2, which contains a 2,6-dimethoxyphenyl- and 1,4-pentadiene-3-one moieties. This compound exhibited inhibitory effects on oseltamivir-resistant strains comparable to its precursor (compound A9), while demonstrating reduced toxicity (CC[SUB]50[/SUB] > 100 μM). Furthermore, we investigated its mechanism of action against anti-influenza virus through immunofluorescence, Western blot, and surface plasmon resonance (SPR) experiments. The results revealed that compound IIB-2 can impede virus proliferation by blocking the export of influenza virus nucleoprotein. Thusly, our findings further emphasize influenza nuclear export as a viable target for designing novel chalcone-like derivatives with potential inhibitory properties that could be explored in future lead optimization studies.

Keywords: Anti-influenza; Influenza virus; MM/PBSA; Nucleoprotein; Ribonucleoprotein complex; SPR.

 
Back
Top Bottom